CURRICULUM VITAE

Name: Tae-Min Kim

Email: tmkim@catholic.ac.kr

Phone: 82-2-2258-7483

Fax: 82-2-2258-7619

Position: Professor

Institution: Department of Medical Informatics, College of Medicine, The Catholic University of Korea

Location: Seoul, Korea

Education:

2003 - 2009	The Catholic University of Korea, Graduate School, Ph.D. in Microbiology
2001 - 2003	The Catholic University of Korea, Graduate School, M.S. in Microbiology
1994 - 2000	The Catholic University of Korea, College of Medicine, Seoul, Korea, M.D. in Medicine

Representative Careers:

2017- Present	Professor, Dept of Medical Informatics, The Catholic University of Korea
	Deputy director, Cancer Research Institute, The Catholic University of Korea
2013 - 2017	Associate Professor , Dept of Medical Informatics, The Catholic University of Korea
2013 – 2013	Research Professor, Cancer Evolution Research Center, Catholic Medical School
2008 - 2012	Research Associate, Center for Biomedical Informatics, Harvard Medical School, MA
2007 - 2008	Research Instructor, Dept of Microbiology, Catholic Medical College
2004 - 2007	Public Health Doctor, Dept of Metabolic Disease, National Institute of Health, Korea

Specialty & Present Interest:
Cancer genomics and Bioinformatics

Representative papers (up to 5):

1. Lee HH, Kim SY, Jung ES, Yoo J, Kim TM. Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases. Gastric Cancer. 2018 Aug 21. doi: 10.1007/s10120-018-0870-6. PMID: 30132154
2. Rhee JK, Jung YC, Kim KR, Yoo J, Kim J, Lee YJ, Ko YH, Lee HH, Cho BC, Kim TM. Impact of tumor purity on immune gene expression and clustering analyses across multiple cancer types. Cancer Immunol Res. 2018 Jan;6(1):87-97.
3. Cortes-Ciriano I, Lee S, Park WY, Kim TM*, Park PJ*. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017 Jun 6;8:15180. (*co-correspondence)
4. Kim HR, Kang HN, Shim HS, Kim EY, Kim J, Kim DJ, Lee JG, Lee CY, Hong MH, Kim SM, Kim H, Pyo KH, Yun MR, Park HJ, Han JY, Youn HA, Ahn MJ, Paik S*, Kim TM*, Cho BC*. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 Jun 1;28(6):1250-1259. (*co-correspondence)

5. Kim TM, Jung SH, An CH, Lee SH, Baek IP, Kim M, Park SW, Rhee JK, Lee SH, Chung YJ. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin Cancer Res. 2015 Oct 1;21(19):4461-72. Pubmed